Evidence map›Paper›PMID 42150146›Full record

SynthesisJCO precision oncology2026

Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors.

Agustina Oller, Patrick Kemmeren, Daniela Perotti, Harm van Tinteren, Arnauld Verschuur, Filippo Spreafico, Jesper Brok, Rhoikos C J Furtwängler, Tanzina Chowdhury, Reem Al-Saadi and 11 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Agustina OllerPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0001-8183-3167
Patrick KemmerenPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0003-2237-7354
Daniela PerottiPredictive Medicine: Molecular Bases of Genetic Risk, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.ORCID 0000-0002-6703-2889
Harm van TinterenPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0002-4626-8702
Arnauld VerschuurDepartment of Pediatric Haematology-Oncology, La Timone Children's Hospital, AP-HM, Marseille, France.ORCID 0000-0003-1070-4442
Filippo SpreaficoPaediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-5587-3509
Jesper BrokDepartment of Paediatric Oncology and Haematology, Rigshospitalet, Copenhagen, Denmark.
Rhoikos C J FurtwänglerDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital University Hospital, University of Bern, Bern, Switzerland.ORCID 0000-0002-1967-8343
Tanzina ChowdhuryDepartment of Pediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
Reem Al-SaadiDevelopmental Biology and Cancer Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
Gordan M VujanicDepartment of Pathology, Sidra Medicine, Doha, Qatar.ORCID 0000-0003-0726-6939
Amy L TreeceDepartment of Pathology and Laboratory Medicine, Children's of Alabama, Birmingham, AL.
Jarno DrostPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0002-2941-6179
Martine van GrotelPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0002-8849-8573
Elizabeth A MullenDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-6704-0002
Nicholas F EvageliouDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0002-5567-0007
Norbert GrafDepartment of Pediatric Hematology and Oncology, Saarland University, Homburg, Saarland, Germany.ORCID 0000-0002-2248-323X
Andrew L HongDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA.ORCID 0000-0003-0374-1667
Manfred GesslerDevelopmental Biochemistry, Theodor-Boveri-Institute/Biocenter, Julius-Maximilians-University Wuerzburg, Würzburg, Germany.ORCID 0000-0002-7915-6045
James I GellerPeckham Center for Cancer and Blood Disorders, Rady Children's Hospital, San Diego, CA.ORCID 0000-0001-5181-116X
Marry M van den Heuvel-EibrinkPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0002-7760-879X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMolecular biomarkers are increasingly used for risk stratification, particularly in up-front surgery settings (Children's Oncology Group trials), whereas in preoperative chemotherapy setting, the ongoing International Society of Pediatric Oncology (SIOP)-Renal Tumor Study Group-2016 UMBRELLA study aims to validate selected biomarkers for future risk-adapted treatment strategies. This systematic review summarizes all literature on the prognostic value of these biomarkers. MATERIALS AND

methodsA systematic literature review (PubMed and Embase; up to January 2025) included studies with ≥50 de novo Wilms tumors (WTs). Eligible biomarkers included copy number variations; 1q gain, 1p and/or 16q loss of heterozygosity (LOH)/loss, 12 gain, 14q loss, 22 loss, 11p15 LOH/loss of imprinting (LOI), and structural somatic variants (

resultsLow-bias multivariable/stratified analyses identified 1q gain as worse EFS and 1p and/or 16q LOH/loss as worse EFS/OS prognostic factors, in up-front nephrectomy settings. Preoperative chemotherapy settings revealed similar trends with lacking significance.

conclusion1q gain and 1p and/or 16q LOH/loss emerge as independent prognostic biomarkers in up-front nephrectomy settings. Evidence remains limited in preoperative chemotherapy settings, particularly when using SIOP-oriented treatment algorithms. Prognostic value of

Indexed as

Biomarkers, TumorKidney NeoplasmsWilms TumorHumansLoss of HeterozygosityPrognosisBiomarkers, Tumor

Identifiers

PMID42150146
PMCPMC13193183

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.